News & Investors

Investor Relations

Corporate Profile

Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.

Stock Price

Nov 27, 2021 7:05 AM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News
Nov 12, 2021
Forma Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Nov 05, 2021
Forma Therapeutics to Report Third Quarter 2021 Financial Results and Provide Business Update on November 12, 2021
Nov 04, 2021
Forma Therapeutics Announces Four Presentations on Etavopivat and Olutasidenib at Upcoming 2021 ASH Annual Meeting
Upcoming Events
Dec 13, 2021
8:00 AM EST
Investor Briefing to Discuss Clinical Data Presentations at the ASH Annual Meeting
Learn more
Nov 18, 2021
8:00 AM GMT
Jefferies London Healthcare Conference
Learn more
Nov 12, 2021
8:00 AM EST
Forma Therapeutics Third Quarter 2021 Financial Results and Business Update
Learn more